Related Experiment Videos
[Ciprofloxacin in combination with other antimicrobial substances]
P M Shah1, D Mellinghoff, W Stille
1Arbeitsgruppe Infektiologie, Zentrum der Inneren Medizin, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt/Main.
Arzneimittel-Forschung
|March 1, 1988
Summary
Ciprofloxacin combined with beta-lactams or tobramycin showed no antagonism against enterococcus and pseudomonas species. Testing revealed potential for slight synergistic antibacterial effects, not reduced efficacy.
Area of Science:
- Microbiology and Infectious Diseases
- Pharmacology and Therapeutics
Context:
- Enterococcus and Pseudomonas species are significant human pathogens.
- Antibiotic resistance necessitates evaluating combination therapies.
- Ciprofloxacin, a fluoroquinolone, and beta-lactams/aminoglycosides are common antibiotics.
Purpose:
- To assess the in vitro antibacterial and bactericidal activity of ciprofloxacin in combination with azlocillin, imipenem, mezlocillin, or tobramycin.
- To determine potential synergistic, antagonistic, or additive effects of these antibiotic combinations against specific bacterial strains.
Summary:
- Checkerboard titration showed no synergy or antagonism between ciprofloxacin and azlocillin, imipenem, mezlocillin, or tobramycin against enterococcus and pseudomonas.
- Bactericidal activity testing (using 1x MIC of each agent in combination) did not show reduced efficacy compared to higher concentrations of single agents.
- Antagonism is unlikely; a slight synergistic effect may occur when ciprofloxacin is combined with the tested beta-lactams or tobramycin.
Impact:
- Provides crucial in vitro data for guiding clinical decisions on antibiotic combinations.
- Suggests that combining ciprofloxacin with certain beta-lactams or tobramycin is a safe strategy regarding efficacy.
- Highlights the potential for enhanced therapeutic outcomes through specific antibiotic pairings.